Girentuximab
- Generic Name
- Girentuximab
- Drug Type
- Biotech
- CAS Number
- 916138-87-9
- Unique Ingredient Identifier
- 539B57DFJF
- Background
Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
- Indication
Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.
Telix Pharmaceuticals to Present Advanced Prostate and Kidney Cancer Therapies at ASCO GU 2025
• Telix Pharmaceuticals will showcase four presentations at ASCO GU 2025, including preliminary data from the CUPID study demonstrating proof-of-concept for their alpha therapy candidate in prostate cancer.
• The company's Phase 3 ProstACT GLOBAL trial investigating TLX591 for PSMA-positive metastatic castration-resistant prostate cancer is actively enrolling patients across multiple regions.
• Two groundbreaking STARLITE trials will present updates on TLX250 combined with immunotherapy for clear cell renal cell carcinoma, positioning it as the first potential CAIX-targeting radiotherapy.
TLX250-CDx Shows High Accuracy in Kidney Cancer Imaging: Phase 3 ZIRCON Trial Published
• The Phase 3 ZIRCON trial results, published in _The Lancet Oncology_, demonstrate the high accuracy of TLX250-CDx in detecting clear cell renal cell carcinoma (ccRCC).
• TLX250-CDx, a PET imaging agent, offers a non-invasive method for characterizing indeterminate renal masses, potentially reducing unnecessary surgeries.
• The trial's findings support TLX250-CDx as a breakthrough technology for early and accurate diagnosis of kidney cancer, informing patient management and treatment decisions.
• Telix is working to resubmit the BLA for TLX250-CDx to the FDA, targeting a commercial launch in 2025, which could make it the first targeted PET agent for kidney cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath